Pre-Op Digifab Before CABG Prevents Post-Op AKI In Patients At High Risk
KEY POINTS: Ouabain, a cardiac glycoside that is structurally similar to digoxin, has been shown to impair renal function in animal models. This finding suggests... Read more.
FARES II: PCC Improves Hemostasis and Decreases Transfusions in Adult Cardiac Surgery Patients with Coagulopathy
KEY POINTS: Significant bleeding is a common complication of cardiac surgery. Frozen plasma is the standard therapy but prothrombin complex concentrate offers an... Read more.
DAPA TAVI: Dapagliflozin Reduced All Cause Death or Worsening HF In Elderly Patients Undergoing TAVI
KEY POINTS: SGLT2 inhibitors reduce admission for heart failure exacerbations. Clinical trials for SGLT2 inhibitors have historically excluded patients with aortic... Read more.
Consistent Efficacy and Safety of Finerenone in Women and Men: A Secondary Analysis of the FINEARTS-HF Trial
KEY POINTS: Historically women have been underrepresented in cardiovascular clinical trials, however, rates of Heart Failure with Preserved Ejection Fraction are... Read more.
In a Hierarchical Composite Outcome, Finerenone Shows Reduction in HF Exacerbations in HFmrEF or HFpEF: FINEARTS
KEY POINTS: Hierarchical analysis prioritizing significant events more effectively traditional composite outcomes, offering clearer clinical guidance In a pre-specified... Read more.
Finerenone Raises Potassium but Retains Clinical Benefits with Protocol-directed Surveillance and Dose Adjustment: FINEARTS
KEY POINTS: Finerenone, a non-steroidal mineralocorticoid (MRA), increased serum potassium levels more often than placebo. However, adverse events from hyperkalemia... Read more.
Exenatide, a GLP-1 Analog, Did Not Reduce Organ Injury, Stroke or Death During Cardiac Surgery: GLORIOUS Trial
KEY POINTS: Exenatide is a glucaon-like-peptide-1 agonist (GLP-1) improves glycemic control, and other medications in this class, appear to reduce the risk of cardiovascular... Read more.
FINEARTS-HF – Finerenone Improves outcomes in in HF with mildly reduced and preserved ejection fraction
KEY POINTS: There is a scarcity of treatments for HFpEF and HFmrEF with a high burden of disease worldwide In this randomized, double-blind, placebo-controlled trial,... Read more.